DEF 14A: Teladoc Health Seeks Stockholder Approval for Incentive Award Plan Amendment

Teladoc Health is asking stockholders to approve an amendment to its 2023 Incentive Award Plan to increase the number of shares available for issuance by 6,850,000 shares, aiming to attract, motivate, and retain qualified personnel.

Summary

• Teladoc Health is seeking stockholder approval to amend its 2023 Incentive Award Plan to increase the share reserve by 6,850,000 shares.
• The company believes this increase is crucial for attracting, motivating, and retaining talent in a competitive market.
• The proposed share increase is expected to last approximately one year.
• The company's three-year average run rate is 5.12%, and it projects a run rate of approximately 4% for 2025.
• As of February 28, 2025, the company's overhang was 13.8%, and it is expected to be 16.7% if the amendment is approved.
• The company's total stock-based compensation expense has decreased from $217.9 million in 2022 to $146.0 million in 2024.
• The 2023 Incentive Award Plan includes governance practices such as a minimum vesting condition, no evergreen provision, and no repricing without stockholder approval.
• The Board recommends voting FOR the amendment.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the details of the proposed amendment to the incentive award plan. While it emphasizes the importance of the amendment for attracting and retaining talent, it also acknowledges the need to manage dilution and control expenses. The sentiment is neutral to slightly positive, reflecting a strategic approach to compensation.

Positives

• The company's stock-based compensation expense has decreased from $217.9 million in 2022 to $146.0 million in 2024.
• The 2023 Incentive Award Plan includes governance practices such as a minimum vesting period of one year for awards.
• The company's run rate is projected to decrease to approximately 4% for 2025.

Risks

• If the amendment is not approved, the company may have to shift to a more cash-oriented compensation program, which could negatively impact cash management and operating expenses.
• Failure to approve the amendment could hinder the company's ability to attract and retain talent in a competitive market.

Future Outlook

The company expects the proposed share increase to last approximately one year and projects a run rate of approximately 4% for 2025.

Industry Context

The company competes for talent with other healthcare and technology companies, including those in Silicon Valley, where equity incentives are necessary to attract and retain critical employees.

Comparison to Industry Standards

• The company's peer group for executive compensation includes healthcare technology and SaaS-based software solutions providers.
• The company's peer group includes companies such as Akamai Technologies, DocuSign, and Twilio.
• The company's compensation arrangements are designed to be competitive with those of its peers.

Related Party Transactions

• The company has a contract with Cedar Gate Technologies for data and value-based analytics tools, where Mr. Snow, the Chairman of the Board, is the Chief Executive Officer and owns approximately 10% of its outstanding capital stock.
• The company paid $517,250 to Cedar Gate in 2024 for data and value-based analytics tools.

Stakeholder Impact

• Approval of the amendment is intended to benefit stockholders by enabling the company to attract and retain talent, which is expected to drive long-term value.
• Employees are expected to benefit from the continued availability of equity incentives, which align their interests with those of stockholders.
• Failure to approve the amendment could negatively impact the company's ability to attract and retain talent, potentially affecting its performance and stakeholder value.

Next Steps

• Stockholder vote on the proposed amendment to the 2023 Incentive Award Plan at the Annual Meeting on May 22, 2025.

Key Dates

Keywords

incentive award plan, equity compensation, stock options, restricted stock units, performance stock units, executive compensation, dilution, run rate, overhang, talent retention, corporate governance, proxy statement, Teladoc Health